Related Experiment Videos
Normal MPS excretion, but dermatan sulphaturia, combined with a mild Maroteaux-Lamy phenotype
T Tønnesen1, H N Gregersen, F Güttler
1John F Kennedy Institute, Glostrup, Denmark.
Journal of Medical Genetics
|July 1, 1991
Abstract:
A mildly affected Maroteaux-Lamy patient is described. Electrophoretic separation of acid mucopolysaccharides (MPS) in the urine showed an increased excretion of dermatan sulphate in spite of a normal total excretion of MPS.
Insights
A patient with mild Maroteaux-Lamy syndrome showed increased urinary dermatan sulfate excretion. This finding occurred despite normal overall acid mucopolysaccharide levels, highlighting specific metabolic alterations.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Disorders
Background:
- Maroteaux-Lamy syndrome is a rare genetic disorder affecting mucopolysaccharide metabolism.
- It is characterized by a deficiency in the enzyme N-acetylgalactosamine-4-sulfatase, leading to the accumulation of specific glycosaminoglycans.
- Mild cases may present with subtle clinical manifestations and require detailed biochemical analysis for diagnosis.
Observation:
- This study describes a patient with a mild presentation of Maroteaux-Lamy syndrome.
- Urine analysis was performed using electrophoretic separation of acid mucopolysaccharides (MPS).
- The patient exhibited an unusual pattern of MPS excretion.
Findings:
- Electrophoresis revealed a significantly increased excretion of dermatan sulfate in the patient's urine.
- Despite the elevated dermatan sulfate, the total excretion of acid mucopolysaccharides (MPS) remained within the normal range.
- This suggests a specific defect in dermatan sulfate metabolism or breakdown.
Implications:
- The findings highlight the importance of detailed biochemical profiling in diagnosing even mild cases of lysosomal storage diseases.
- This specific urinary excretion pattern may serve as a diagnostic biomarker for Maroteaux-Lamy syndrome.
- Understanding these specific metabolic alterations can inform future therapeutic strategies targeting enzyme replacement or substrate reduction.